- Home
- GDC vs NCNA Comparison
GDC vs NCNA Comparison
Compare GDC & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GDC | NCNA |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United Kingdom |
| Employees | 5 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 4.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GDC | NCNA |
|---|---|---|
| Price | $1.12 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 176.5K | 73.9K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.47 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.15 | $0.95 |
| 52 Week High | $2,974.65 | $4.55 |
Technical Indicators
Market Signals| Indicator | GDC | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 31.93 | 34.43 |
| Support Level | N/A | $0.95 |
| Resistance Level | $2.10 | $1.40 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 0.04 | 22.35 |
Price Performance
Historical ComparisonAbout GDC GD Culture Group Limited
GD Culture Group Ltd operates and manages its business as a single segment and has one operating and reportable segment, the Virtual Content Production. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.